Clinical Trial Update: SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a SARS-CoV-2–specific monoclonal antibody for Post-COVID-19 condition (Long COVID) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-covid-19 Condition

Drugs mentioned

• SARS-CoV-2 specific monoclonal antibody

Snippet

Sponsor: Nancy Klimas | Conditions: Post-COVID / Long-COVID | Phase 2 | Status: RECRUITING